Key Takeaways
- Shares of Rocket Lab declined 9% during pre-market hours following Q2 2026 financial results
- Quarterly revenue reached an all-time high of $234 million, representing a 62% jump year-over-year and surpassing projections
- Forward-looking GAAP gross margin forecast of 29%ā31% for Q3 significantly underperformed against Street expectations of approximately 37.6%
- Shares had surged roughly 27% during the week preceding the earnings announcement, creating conditions for a correction
- Company maintains a robust backlog totaling $2.36 billion, plus recently secured a $397 million contract with the Space Force
Shares of Rocket Lab experienced a sharp 9% decline in Tuesday’s pre-market session following the company’s Q2 2026 earnings release, which failed to satisfy investors despite strong top-line performance.
The aerospace manufacturer delivered quarterly revenue of $234 million, marking a historic high and representing 62% growth compared to the same period last year. This figure narrowly exceeded the Wall Street consensus estimate of $232 million. However, revenue strength alone proved insufficient to support the stock price.
The company reported an adjusted loss of $0.08 per share, falling short of analyst forecasts. The more significant concern emerged from Q3 guidance, with GAAP gross margin projected at 29%ā31%, substantially below the Street’s expectation of approximately 37.6%.
The timing compounded the negative reaction. Shares had climbed approximately 27% during the seven days before the earnings release, creating an elevated baseline that amplified downside vulnerability when profitability metrics disappointed.
The margin compression stems from changes in revenue composition. Satellite platform sales, which carry lower margins, represented a greater proportion of Space Systems revenue during the quarter.
On a non-GAAP basis, gross margin reached 41.5% for Q2, exceeding the 38% analyst consensus. However, this positive surprise was overshadowed by the weaker forward outlook.
Forward Guidance and Iridium Deal Complications
For Q3, management projected revenue ranging from $250 million to $265 million, significantly above the Street’s $235.9 million estimate. Nevertheless, the declining margin trajectory captured investor attention and drove the stock lower.
Non-GAAP gross margin is anticipated to fall to 35%ā37% in Q3, down from the 41.5% achieved in Q2. The company expects adjusted EBITDA losses between $17 million and $23 million for the coming quarter.
The planned $8 billion acquisition of Iridium introduces additional complexity. Management’s Q3 guidance incorporates approximately 41 million preferred shares, raising shareholder dilution concerns.
The stock’s decline began in Monday’s after-hours session and continued into Tuesday morning. Broader market conditions offered no support, with both the S&P 500 and Nasdaq trading relatively flat.
Pipeline Strength and Major Wins
Rocket Lab closed the quarter with a record backlog valued at $2.36 billion, encompassing over 90 missions scheduled for launch.
The previous week brought news of a significant $397 million contract from the U.S. Space Force, covering both development and launch services for Flatellite spacecraft using the Neutron launch vehicle.
Development of Neutron’s first-stage tank continues according to schedule, with delivery to the launch facility expected in Q4. This represents a critical milestone in the company’s long-term expansion strategy.
Earlier this year, Rocket Lab finalized acquisitions of both Mynaric and Motiv, expanding its technological capabilities in spacecraft and integrated space systems.
Analysts maintain a Strong Buy consensus on the stock, with 13 Buy ratings and 4 Hold ratings issued over the last three months. The average analyst price target stands at $110.53, suggesting approximately 38% potential upside from Monday’s closing price.


